# Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia

> **NCT03008616** · PHASE2,PHASE3 · TERMINATED · sponsor: **AMAG Pharmaceuticals, Inc.** · enrollment: 59 (actual)

## Conditions studied

- Severe Preeclampsia

## Interventions

- **BIOLOGICAL:** AMAG-423 (digoxin immune fab)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03008616
- **Lead sponsor:** AMAG Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-12
- **Primary completion:** 2020-08-13
- **Final completion:** 2020-08-13
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** Following a recommendation from the Data and Safety Monitoring Board (DSMB), the study was stopped early for futility. There were no safety concerns raised.
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03008616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03008616, "Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03008616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*